DRIO DarioHealth Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1533998 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.9%
TTM net income YoY19.5%
TTM EPS YoY-67.7%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin57.9%
Operating margin-142.7%
Net margin-159.9%
FCF margin-111.0%
EBITDA margin-141.7%
Returns
ROE-46.6%
ROA-29.6%
ROIC (approx.)-32.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.44x
Current ratio4.20x
Interest coverage-6.81x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $22.36M | $27.04M |
| Cost of revenue | $9.69M | $13.77M |
| Gross profit | $12.66M | $13.27M |
| R&D expense | $13.79M | $24.18M |
| SG&A expense | $15.19M | $20.48M |
| Operating income | -$36.66M | -$57.74M |
| Interest expense | $3.02M | — |
| Pretax income | -$41.61M | -$44.60M |
| Income tax | $105,000 | -$1.85M |
| Net income | -$41.71M | -$42.75M |
| EBITDA | -$36.35M | -$56.42M |
| EPS (basic) | 10.12 | 12.27 |
| EPS (diluted) | 10.12 | 12.27 |
| Weighted avg. shares (diluted) | 3.98M | 2.45M |
| Balance sheet | ||
| Cash & equivalents | $21.80M | $27.76M |
| Short-term investments | $4.21M | — |
| Inventory | $4.32M | $4.75M |
| Current assets | $35.07M | $40.53M |
| PP&E, net | $549,000 | $709,000 |
| Goodwill | $57.43M | $57.43M |
| Intangibles | $15.93M | $18.76M |
| Total assets | $110.08M | $118.88M |
| Current liabilities | $9.32M | $16.64M |
| Short-term debt | — | $5.45M |
| Long-term debt | $30.75M | $23.47M |
| Total debt | $30.75M | $28.92M |
| Total liabilities | $42.15M | $46.87M |
| Shareholders' equity | $67.92M | $72.02M |
| Net debt | $8.94M | $1.16M |
| Shares outstanding | 6.91M | 1.92M |
| Cash flow statement | ||
| Operating cash flow | -$25.94M | -$38.56M |
| Capital expenditure | $142,000 | $138,000 |
| Free cash flow | -$26.08M | -$38.70M |
| Investing cash flow | -$4.34M | -$8.93M |
| Financing cash flow | $24.31M | $38.53M |
| Depreciation & amortization | $307,000 | $1.33M |
| Stock-based compensation | $9.37M | $46,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.